Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its high mortality and resistance to monotherapies.
• Synthetic lethality, particularly targeting Poly (ADP-ribose) polymerase 1 (PARP1), is a promising strategy, but its efficacy in HCC remains limited.
• Identifying novel synthetic lethal partners is crucial for advancing HCC treatment.

Purpose of the Study:

• To identify new synthetic lethal partners for hepatocellular carcinoma (HCC) treatment.
• To investigate the role of Src in mediating resistance to PARP1 inhibition in HCC.
• To evaluate the therapeutic potential of combining Src and PARP1 inhibition in HCC.

Main Methods:

• Utilized a combination therapy approach targeting Src and PARP1 in HCC models.
• Investigated the molecular mechanism of Src-PARP1 interaction and its effect on PARP1 phosphorylation.
• Assessed the anti-tumor efficacy and side effects of the combined therapeutic strategy.

Main Results:

• Src and PARP1 were identified as novel synthetic lethal partners in HCC.
• Combination therapy targeting Src and PARP1 demonstrated significant anti-tumor effects with minimal side effects.
• Src phosphorylates PARP1 at the Y992 residue, a key mechanism driving resistance to PARP1 inhibitors in HCC.

Conclusions:

• Src-mediated PARP1 phosphorylation confers resistance to PARP1 inhibitors in HCC.
• Co-targeting PARP1 and Src represents a viable therapeutic strategy for HCC, particularly for patients resistant to PARP1 inhibitors alone.
• This study highlights a therapeutic window targeting Y992 phosphorylation of PARP1 for improved HCC patient outcomes.